Exact Sciences

Exact argues that JHU has no basis to demand any royalties on sales of Cologuard because the test doesn't use any patents the university licensed to the company.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.

After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.

The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.

The GenomeWeb Index, which now has 32 companies, lost 2.6 percent in September while the Dow Jones Industrial Average gained 2 percent over the same period.

The agency has approved the use of Exact's Cologuard test for average-risk individuals aged 45 and older.

The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.

The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.